#United States #Washington, D.C. #GLP-1 #Ambrosia Biosciences #GIP Antagonist

Ambrosia Biosciences to Present at ObesityWeek 2026

Ambrosia Biosciences Inc., a leading player in drug discovery focused on metabolic disorders, has announced that it will unveil two significant poster presentations at the upcoming ObesityWeek® 2026. This esteemed event, organized by the Obesity Society, is set to take place from November 14 to 17 in Washington, D.C. The presentations will spotlight in-depth research on a couple of innovative therapies aimed at fighting obesity - the GLP-1 receptor agonist and the GIP receptor antagonist.

Presentation Details

The two posters scheduled for presentation are:
1. Discovery and Nonclinical Profile of AMB-895 - This is a novel oral small molecule GLP-1 receptor agonist designed for once-a-week administration.
- Poster #: 463
- Location: Gaylord National Resort & Convention Center, Exhibit Hall BCD
- Date and Time: Sunday, November 15, 2026, from 2:30 PM to 3:30 PM ET

2. Discovery and Nonclinical Profile of AMB-131 - This novel oral small molecule GIP receptor antagonist promises to be a breakthrough therapy in obesity management.
- Poster #: 470
- Location: Gaylord National Resort & Convention Center, Exhibit Hall BCD
- Date and Time: Sunday, November 15, 2026, from 2:30 PM to 3:30 PM ET

These presentations are pivotal as they will provide attendees with unique insights into the nonclinical profiles of these new therapies that have the potential to alter the landscape of obesity treatment.

About Ambrosia Biosciences Inc.

Ambrosia Biosciences, a privately held drug discovery company, is at the forefront of developing next-generation therapies targeting obesity and other metabolic disorders. The company integrates advanced drug design and in-house medicinal chemistry to create a robust pipeline of innovative solutions aimed at improving patient care and reducing treatment complexities while minimizing costs. As part of its mission, Ambrosia aims to expand access to vital cardiometabolic therapies, thereby enhancing overall patient experience.

For more insights, visit Ambrosia Biosciences' official website.

Looking Ahead

Ambrosia's participation in ObesityWeek 2026 underscores its commitment to advancing research in metabolic disorders and provides a platform for the company to share its innovations with a wider audience. This presents a significant opportunity for healthcare professionals and researchers to engage with cutting-edge science that could reshape treatment paradigms for obesity and related metabolic issues. As advancements continue, the medical community anticipates further breakthroughs from Ambrosia that could lead to more effective and accessible treatment options for patients worldwide.

In conclusion, the ObesityWeek 2026 event promises to be a significant gathering for health professionals interested in the latest developments in the field of obesity research and treatment, where Ambrosia Biosciences will undoubtedly play a pivotal role.